Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 12Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Advanced Pancreatic Cancer 3Esophageal Neoplasms 2Biliary Tract Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Staging IV NSCLC 1Squamous Cell Carcinoma of Lung 1Solid Tumor 1Sertoli-Leydig Cell Tumor 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Ovarian gynandroblastoma 1Obesity 1Neurotoxicity Syndromes 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Liver Neoplasms 1HER2-negative Breast Cancer 1HER2+ Breast Cancer 1

Interventions

irinotecan sucrosofate 1Taxes 1Radiosurgery 1Oxaliplatin 1Leucovorin 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pancreatic Cancer Non-resectable × Taxes × Clear all
NCT05047991 2021-09-17

Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 2 Unknown
153 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡